Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

被引:211
|
作者
Escudier, B. [1 ]
Eisen, T. [2 ]
Porta, C. [3 ]
Patard, J. J. [4 ]
Khoo, V. [5 ]
Algaba, F. [6 ]
Mulders, P. [7 ]
Kataja, V. [8 ]
机构
[1] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] NIHR Cambridge Biomed Res Ctr, Cambridge, England
[3] IRCCS San Matteo Univ Hosp Fdn, Dept Med Oncol, Pavia, Italy
[4] Bicetre Hosp, Dept Urol, Le Kremlin Bicetre, France
[5] Royal Marsden NHS Fdn Trust & Inst Canc Res, London, England
[6] Univ Autonoma Barcelona, Dept Pathol, Fundacio Puigvert, E-08193 Barcelona, Spain
[7] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 ED Nijmegen, Netherlands
[8] Kuopio Univ Hosp, Ctr Canc, SF-70210 Kuopio, Finland
关键词
INTERFERON-ALPHA; DOUBLE-BLIND; NEPHRECTOMY; PROGRESSION; OUTCOMES;
D O I
10.1093/annonc/mds227
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:65 / 71
页数:7
相关论文
共 50 条
  • [1] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Escudier, B.
    Porta, C.
    Schmidinger, M.
    Rioux-Leclercq, N.
    Bex, A.
    Khoo, V.
    Gruenvald, V.
    Horwich, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : v58 - v68
  • [2] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Escudier, B.
    Porta, C.
    Schmidinger, M.
    Rioux-Leclercq, N.
    Bex, A.
    Khoo, V.
    Grunwald, V.
    Gillessen, S.
    Horwich, A.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (05) : 706 - 720
  • [3] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Escudier, B.
    Kataja, V.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : v137 - v139
  • [4] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Escudier, B.
    Porta, C.
    Schmidinger, M.
    Algaba, F.
    Patard, J. J.
    Khoo, V.
    Eisen, T.
    Horwich, A.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 : 49 - 56
  • [5] Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    Powles, T.
    Albiges, L.
    Bex, A.
    Comperat, E.
    Gruenwald, V.
    Kanesvaran, R.
    Kitamura, H.
    McKay, R.
    Porta, C.
    Procopio, G.
    Schmidinger, M.
    Suarez, C.
    Teoh, J.
    de Velasco, G.
    Young, M.
    Gillessen, S.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 (08) : 692 - 706
  • [6] Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Jelic, S.
    Sotiropoulos, G. C.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : v59 - v64
  • [7] Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Vogel, A.
    Cervantes, A.
    Chau, I.
    Daniele, B.
    Llovet, J.
    Meyer, T.
    Nault, J. -C.
    Neumann, U.
    Ricke, J.
    Sangro, B.
    Schirmacher, P.
    Verslype, C.
    Zech, C. J.
    Arnold, D.
    Martinelli, E.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 238 - 255
  • [8] Renal cell carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    Escudier, B.
    Kataja, V.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 81 - 82
  • [9] Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Powles, T.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (03) : 422 - 423
  • [10] Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Dummer, R.
    Hauschild, A.
    Guggenheim, M.
    Jost, L.
    Pentheroudakis, G.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : v194 - v197